GE Healthcare
Nomura Inaugural US Industrials Summit

Pascale Witz
President & CEO, Medical Diagnostics
Caution Concerning Forward-Looking Statements:
This document contains “forward-looking statements” – that is, statements related to future, not past, events. In this context, forward-looking statements often address our expected future business and financial performance and financial condition, and often contain words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “seek,” “see,” or “will.” Forward-looking statements by their nature address matters that are, to different degrees, uncertain. For us, particular uncertainties that could cause our actual results to be materially different than those expressed in our forward-looking statements include: current economic and financial conditions, including volatility in interest and exchange rates, commodity and equity prices and the value of financial assets; potential market disruptions or other impacts arising in the United States or Europe from developments in the European sovereign debt situation; the impact of conditions in the financial and credit markets on the availability and cost of General Electric Capital Corporation’s (GECC) funding and on our ability to reduce GECC’s asset levels as planned; the impact of conditions in the housing market and unemployment rates on the level of commercial and consumer credit defaults; changes in Japanese consumer behavior that may affect our estimates of liability for excess interest refund claims (Grey Zone); potential financial implications from the Japanese natural disaster; our ability to maintain our current credit rating and the impact on our funding costs and competitive position if we do not do so; the adequacy of our cash flow and earnings and other conditions which may affect our ability to pay our quarterly dividend at the planned level; our ability to convert customer wins (which represent pre-order commitments) into orders; the level of demand and financial performance of the major industries we serve, including, without limitation, air and rail transportation, energy generation, real estate and healthcare; the impact of regulation and regulatory, investigative and legal proceedings and legal compliance risks, including the impact of financial services regulation; strategic actions, including acquisitions, joint ventures and dispositions and our success in completing announced transactions and integrating acquired businesses; and numerous other matters of national, regional and global scale, including those of a political, economic, business and competitive nature. These uncertainties may cause our actual future results to be materially different than those expressed in our forward-looking statements. We do not undertake to update our forward-looking statements.

“This document may also contain non-GAAP financial information. Management uses this information in its internal analysis of results and believes that this information may be informative to investors in gauging the quality of our financial performance, identifying trends in our results and providing meaningful period-to-period comparisons. For a reconciliation of non-GAAP measures presented in this document, see the accompanying supplemental information posted to the investor relations section of our website at www.ge.com.”

“Effective January 1, 2011, we reorganized our segments. We have reclassified prior-period amounts to conform to the current-period's presentation.”

“In this document, “GE” refers to the Industrial businesses of the Company including GECS on an equity basis. “GE (ex. GECS)” and/or “Industrial” refer to GE excluding Financial Services.”
$18B broad technology portfolio

Diagnostic & Clinical Equipment
~46% of revenue
- Diagnostic imaging
- Clinical products
- Home health

$8.3B

Information Tech. and Services
~34% of revenues
- Clinical and Administrative
- Enterprise Imaging
- Connectivity & knowledge solutions
- Equipment service solutions

$6.1B

Molecular Medicine
~20% of revenues
- Bio-process
- Protein & cell sciences
- Contrast media
- Molecular pathology

$3.7B

* Revenue represent 2011 results
Demographic trends escalating demand

Populations aging

- 2030: the number of people over 65 will
  - Increase 140% in developing world
  - Increase 51% in developed world
- 48.6% relative lifetime healthcare expenditure is expended after age 65

...and demand is growing

- Global number of Alzheimer’s patients will grow from 36 million in 2009 to 66 million in 2030 and 115 million in 2050
- Global number of cancer patients is predicted to grow from 10.1 million in 2000 to 15.7 million in 2020
- US: chronic disease up 80% and spending up 260% over last 20 years. Spend to increase 2.5X by 2023

Healthcare expenditures outpacing GDP growth
GEHC - Enables Personalized Medicine

Personalized medicine multiple components - GE Healthcare makes it happen TODAY

- Biomarker development
- Integrated Dx/Rx R&D
- Right drug to the right patient
- Pathology, Biopsy analysis
- Radiology as biomarker
- New diagnostics assays

GE Healthcare makes it happen TODAY
Radiology & pathology - enablers of personalized medicine

Early detection → Complete patient diagnostics → Personalized therapy

GP → Radiologist → Pathologist → Oncologist

Screening → Imaging → Biopsy analysis → Treatment decision and monitoring

Suspicion of cancer, more tests needed
Radiology imaging for mass confirmation, location
Therapy selection limited

Definitive diagnostic... tissue-based today
Advanced radiology... activity, molecular
Enables specific therapy selection
GE continues to lead the integration of diagnostic solutions

- Clarient
- Omnyx
- New tech

Integrated pathology solution

REVOLUTIONARY

Advanced Diagnostics: combined Radiology & Pathology

INCREMENTAL BREAKTHROUGH

Clarient

GE solutions resulting in better patient outcomes
Better companion diagnostics needed for Rx development

- Diagnostic deals lead pharma BD in 2011
- Recent FDA Rx+Dx approvals
- 2011-2016 IP cliff impact on sales
- Pharma R&D cost and attrition
- Biomarker in >80% of Pharma pipeline

Rx+Dx will drive pharma growth
Alzheimer’s Disease ...  
... an unmet need for complete Dx solution

Current

Screening

Diagnosis

Treatment

Monitoring

If cognitively impaired

Late disease detection

Rule Out Other diseases

Symptomatic drugs

Clinical follow-up

If demented

Genetic testing

Blood Test

Flutemetamol

Hippocampal volume (MRI)

Flutemetamol

Amyloid PET

Vasogenic Oedema (MRI)

Risk Stratification

Early detection

Disease Modifying Drug

Proof of target engagement

Future

Enabling First Generation of Disease Modifying Drugs

The imaging agents described are not approved for use by the FDA or any other health regulatory agency
Medical Diagnostics - Broad range of technologies with prominent global presence

- Leader in in-vivo imaging
- Clarient – molecular Dx & Pharma R&D hub
- Proprietary technology for R&D and clinical use
- Innovative digital solutions for pharma and clinical labs

>53,000 GEHC employees with WW infrastructure
Personalized medicine is the next revolution in patient care and GE Healthcare, Medical Diagnostics is leading the way...